REFERENCES
1. Pose E, Piano S, Juanola A, Ginès P. Hepatorenal syndrome in cirrhosis. Gastroenterology. 2024;166:588-604.e1.
2. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687.
3. Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4:23.
4. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968-74.
5. Belcher JM. Hepatorenal syndrome: pathophysiology, diagnosis, and treatment. Med Clin North Am. 2023;107:781-92.
6. Gaytan SL, Beaven E, Gadad SS, Nurunnabi M. Progress and prospect of nanotechnology for cardiac fibrosis treatment. Interdiscip Med. 2023;1:e20230018.
7. Solé C, Solà E, Huelin P, et al. Characterization of inflammatory response in hepatorenal syndrome: relationship with kidney outcome and survival. Liver Int. 2019;39:1246-55.
8. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385-96.
9. Dai H, Fan Q, Wang C. Recent applications of immunomodulatory biomaterials for disease immunotherapy. Exploration. 2022;2:20210157.
10. Sun S, Ma S, Cai Y, et al. A single-cell transcriptomic atlas of exercise-induced anti-inflammatory and geroprotective effects across the body. Innovation. 2023;4:100380.
11. Xu L, Shao Z, Fang X, et al. Exploring precision treatments in immune-mediated inflammatory diseases: harnessing the infinite potential of nucleic acid delivery. Exploration. 2025;5:20230165.
12. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272-84.
13. Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022;19:112-34.
14. Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41:653-64.
15. Shareghi-Oskoue O, Aghebati-Maleki L, Yousefi M. Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure. Stem Cell Res Ther. 2021;12:454.
16. Regmi S, Pathak S, Kim JO, Yong CS, Jeong JH. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019;98:151041.
17. Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023;14:66.
18. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
19. Mizenko RR, Feaver M, Bozkurt BT, et al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. 2024;13:e12510.
20. Brigstock DR. Extracellular vesicles in organ fibrosis: mechanisms, therapies, and diagnostics. Cells. 2021;10:1596.
21. Huang Y, Arab T, Russell AE, et al. Toward a human brain extracellular vesicle atlas: characteristics of extracellular vesicles from different brain regions, including small RNA and protein profiles. Interdiscip Med. 2023;1:e20230016.
22. Chiabotto G, Semnani A, Ceccotti E, Bruno S. Extracellular vesicles: emerging therapeutic agents for liver fibrosis. Extracell Vesicles Circ Nucl Acids. 2025;6:216-44.
23. Mincheva G, Moreno-Manzano V, Felipo V, Llansola M. Extracellular vesicles from mesenchymal stem cells improve neuroinflammation and neurotransmission in hippocampus and cognitive impairment in rats with mild liver damage and minimal hepatic encephalopathy. Stem Cell Res Ther. 2024;15:472.
24. Li R, Wang C, Chen X, et al. Phosphatidylserine-mediated uptake of extracellular vesicles by hepatocytes ameliorates liver ischemia-reperfusion injury. Apoptosis. 2025;30:69-82.
25. Miao L, Yu C, Guan G, et al. Extracellular vesicles containing GAS6 protect the liver from ischemia-reperfusion injury by enhancing macrophage efferocytosis via MerTK-ERK-COX2 signaling. Cell Death Discov. 2024;10:401.
26. Zhang X, Che X, Zhang S, et al. Mesenchymal stem cell-derived extracellular vesicles for human diseases. Extracell Vesicles Circ Nucl Acids. 2024;5:64-82.
27. Li B, Qi C, Zhang Y, et al. Frontier role of extracellular vesicles in kidney disease. J Nanobiotechnology. 2024;22:583.
28. Kosanović M, Milutinović B, Kutzner TJ, Mouloud Y, Bozic M. Clinical prospect of mesenchymal stromal/stem cell-derived extracellular vesicles in kidney disease: challenges and the way forward. Pharmaceutics. 2023;15:1911.
29. Ji C, Zhang J, Shi H, et al. Single-cell RNA transcriptomic reveal the mechanism of MSC derived small extracellular vesicles against DKD fibrosis. J Nanobiotechnology. 2024;22:339.
30. Pan L, Garcia SG, Font-Morón M, et al. Beyond preclinical promise: can mesenchymal stromal cell-derived extracellular vesicles reliably target tubular epithelial cells? Extracell Vesicles Circ Nucl Acids. 2025;6:580-93.
31. Wu T, Liu Y, Wang S, Shi C. MSC-derived extracellular vesicles: roles and molecular mechanisms for tissue repair. Int J Nanomedicine. 2025;20:7953-74.
32. Ceccotti E, Saccu G, Herrera Sanchez MB, Bruno S. Naïve or engineered extracellular vesicles from different cell sources: therapeutic tools for kidney diseases. Pharmaceutics. 2023;15:1715.
33. Liu L, Zheng CX, Zhao N, et al. Mesenchymal stem cell aggregation-released extracellular vesicles induce CD31+ EMCN+ vessels in skin regeneration and improve diabetic wound healing. Adv Healthc Mater. 2023;12:e2300019.
34. Yang J, Li Y, Jiang S, et al. Engineered brain-targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma. Exploration. 2025;5:20240039.
35. Yang J, Wu S, He M. Engineered exosome-based senolytic therapy alleviates stroke by targeting p21+CD86+ microglia. Exploration. 2025;5:20240349.
36. Zheng C, Sui B, Zhang X, et al. Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes. J Extracell Vesicles. 2021;10:e12109.
37. Krones E, Eller K, Pollheimer MJ, et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol. 2017;67:110-9.
38. Li YY, Ma B, Lu JW, et al. Lysosome-featured cell aggregate-released extracellular vesicles regulate iron homeostasis and alleviate post-irradiation endothelial ferroptosis for mandibular regeneration. Adv Sci. 2025;12:e05070.
39. Ommati MM, Mohammadi H, Mousavi K, et al. Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function. Liver Res. 2021;5:171-80.
40. Zhang S, Zhang K, Zheng CX, et al. D-mannose alleviates type 2 diabetes and rescues multi-organ deteriorations by controlling release of pathological extracellular vesicles. Exploration. 2025;5:20240133.
41. Shao M, Zhang X, Sun J, et al. Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing gli1 degradation. Exploration. 2025;5:70000.
42. Ying SQ, Cao Y, Zhou ZK, et al. Hepatocyte-derived tissue extracellular vesicles safeguard liver regeneration and support regenerative therapy. J Nanobiotechnology. 2024;22:521.
43. Ghallab A, González D, Strängberg E, et al. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis. J Hepatol. 2024;80:268-81.
44. Wang M, Qin T, Zhang Y, et al. Toll-like receptor 4 signaling pathway mediates both liver and kidney injuries in mice with hepatorenal syndrome. Am J Physiol Gastrointest Liver Physiol. 2022;323:G461-76.
45. Liam-Or R, Faruqu FN, Walters A, et al. Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent. Nat Nanotechnol. 2024;19:846-55.
46. Zhang K, Li R, Chen X, et al. Renal endothelial cell-targeted extracellular vesicles protect the kidney from ischemic injury. Adv Sci. 2023;10:e2204626.
47. Mao J, Li C, Wu F, et al. MSC-EVs transferring mitochondria and related components: a new hope for the treatment of kidney disease. Front Immunol. 2022;13:978571.
48. Jovic D, Yu Y, Wang D, et al. A brief overview of global trends in MSC-based cell therapy. Stem Cell Rev Rep. 2022;18:1525-45.
49. Zaripova LN, Midgley A, Christmas SE, et al. Mesenchymal stem cells in the pathogenesis and therapy of autoimmune and autoinflammatory diseases. Int J Mol Sci. 2023;24:16040.
50. Chen J, Zheng CX, Jin Y, Hu CH. Mesenchymal stromal cell-mediated immune regulation: a promising remedy in the therapy of type 2 diabetes mellitus. Stem Cells. 2021;39:838-52.
51. Deptuła M, Brzezicka A, Skoniecka A, Zieliński J, Pikuła M. Adipose-derived stromal cells for nonhealing wounds: emerging opportunities and challenges. Med Res Rev. 2021;41:2130-71.
52. Mathew SA, Naik C, Cahill PA, Bhonde RR. Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis. Cell Mol Life Sci. 2020;77:253-65.
53. Kalluri R. The biology and function of extracellular vesicles in immune response and immunity. Immunity. 2024;57:1752-68.
54. Visnovitz T. Extracellular vesicles: biology and therapeutic applications. Int J Mol Sci. 2024;25:13034.
55. Lu W, Allickson J. Mesenchymal stromal cell therapy: progress to date and future outlook. Mol Ther. 2025;33:2679-88.
56. Porreca S, Mennella A, Frasca L. The role of CXCL4 in systemic sclerosis: DAMP, auto-antigen and biomarker. Int J Mol Sci. 2025;26:2421.
57. Chen R, Zou J, Liu J, Kang R, Tang D. DAMPs in the immunogenicity of cell death. Mol Cell. 2025;85:3874-89.
58. Qu B, Xie T, Xie Y, et al. Interleukin-17 A and diabetic kidney disease: emerging evidence on its pathogenic role and targeted modulation. Acta Diabetol. 2025;Epub ahead of print.
